Jamie Case

Jamie Case

Auto-generated profile, based on publicly available information

Jamie Case

Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Experimental Hematology
Verified
Journal Article
Closed access
JCJamie Case
Jamie Case
LMLaura E. Mead
Laura E. Mead
WBWaylan K. Bessler
Waylan K. Bessler
DPDaniel Prater
Daniel Prater
HWHilary A. White
Hilary A. White
DIDavid A. Ingram
David A. Ingram

21 January 2009 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
FTFrank Timmermans
Frank Timmermans
JPJean Plum
Jean Plum
MYMervin C. Yoder
Mervin C. Yoder
DIDavid A. Ingram
David A. Ingram
Bart VandekerckhoveBart Vandekerckhove
Bart Vandekerckhove
JCJamie Case
Jamie Case
Introduction The proof‐of‐concept in vivo: the cell, the read‐out and the animal model EPCs defined in vitro: the achilles heel in EPC biology Summary In the past decade, researchers have gained important insights on the role of bone marrow (BM)‐derived cells in adult neovascularization. A subset of BM‐derived cells, called endothelial progenitor cells (EPCs), has been of particular interest, as these cells were suggested to home to sites of neovascularization and neoendothelialization and differentiate into endothelial cells (ECs) in situ, a process referred to as postnatal vasculogenesis. Therefore, EPCs were proposed as a potential regenerative tool for treating human vascular disease and a possible target to restrict vessel growth in tumour pathology. However, conflicting results have been reported in the field, and the identification, characterization, and exact role of EPCs in vascular biology is still a subject of much discussion. The focus of this review is on the controversial issues in the field of EPCs which are related to the lack of a unique EPC marker, identification challenges related to the paucity of EPCs in the circulation, and the important phenotypical and functional overlap between EPCs, haematopoietic cells and mature ECs. We also discuss our recent findings on the origin of endothelial outgrowth cells (EOCs), showing that this in vitro defined EC population does not originate from circulating CD133+ cells or CD45+ haematopoietic cells.

29 March 2007 in Leukemia
Verified
Journal Article
Open access
PDF file
DPD N Prater
D N Prater
JCJ Case
J Case
DID A Ingram
D A Ingram
MYMervin C. Yoder
Mervin C. Yoder
Since 1997, postnatal vasculogenesis has been purported to be an important mechanism for neoangiogenesis via bone marrow (BM)-derived circulating endothelial progenitor cells (EPCs). Based on this paradigm, EPCs have been extensively studied as biomarkers to assess severity of cardiovascular disease and as a cell-based therapy for several human cardiovascular disorders. In the majority of studies to date, EPCs were identified and enumerated by two primary methodologies; EPCs were obtained and quantified following in vitro cell culture, or EPCs were identified and enumerated by flow cytometry. Both methods have proven controversial. This review will attempt to outline the definition of EPCs from some of the most widely cited published reports in an effort to provide a framework for understanding subsequent studies in this rapidly evolving field. We will focus this review on studies that used cell culture techniques to define EPCs.

1 April 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
JMJulie A. Mund
Julie A. Mund
MEMyka L. Estes
Myka L. Estes
MYMervin C. Yoder
Mervin C. Yoder
DIDavid A. Ingram
David A. Ingram
JCJamie Case
Jamie Case
Objective—: We sought to identify and characterize 2 distinct populations of bona fide circulating endothelial cells, including the endothelial colony-forming cell (ECFC), by polychromatic flow cytometry (PFC), colony assays, immunomagnetic selection, and electron microscopy. Methods and Results—: Mononuclear cells from human umbilical cord blood and peripheral blood were analyzed using our recently published PFC protocol. A population of cells containing both ECFCs and mature circulating endothelial cells was determined by varying expressions of CD34, CD31, and CD146 but not AC133 and CD45. After immunomagnetic separation, these cells failed to form hematopoietic colonies, yet clonogenic endothelial colonies with proliferative potential were obtained, thus verifying their identity as ECFCs. The frequency of ECFCs were increased in cord blood and were extremely rare in the peripheral blood of healthy adults. We also detected another mature endothelial cell population in the circulation that was apoptotic. Finally, when comparing this new protocol with a prior method, we determined that the present protocol identifies circulating endothelial cells, whereas the earlier protocol identified extracellular vesicles. Conclusion—: Two populations of circulating endothelial cells, including the functionally characterized ECFC, are now identifiable in human cord blood and peripheral blood by PFC.

1 November 2008 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
JCJamie Case
Jamie Case
DIDavid A. Ingram
David A. Ingram
LHLaura S. Haneline
Laura S. Haneline
Circulating endothelial progenitor cells (EPCs) in adult human peripheral blood were identified in 1997. Since their original identification, EPCs have been extensively studied as biomarkers to assess the risk of cardiovascular disease in human subjects and as a potential cell therapeutic for vascular regeneration. EPCs are exposed to oxidative stress during vascular injury as residents of blood vessel walls or as circulating cells homing to sites of neovascularization. Given the links between oxidative injury, endothelial cell dysfunction, and vascular disease, recent investigation has focused on the responses of EPCs to oxidant stress and the molecular mechanisms that control redox regulation in these specialized cells. In this review, we discuss the various cell and flow-cytometric techniques used to define and isolate EPCs from circulating blood and the current human and mouse genetic data, which offer insights into redox control in EPC biology and angiogenesis. Finally, we review how EPC responses to oxidant stress may be a critical determinant in maintaining the integrity and function of the cardiovascular system and how perturbations of redox control in EPCs may lead to various human diseases. Antioxid. Redox Signal. 10, 1895–1907.

1 July 2008 in Pediatric Research
Verified
Journal Article
Closed access
MJM Jawad Javed
M Jawad Javed
LMLaura E Mead
Laura E Mead
DPDaniel Prater
Daniel Prater
WBWaylan K Bessler
Waylan K Bessler
DFDavid Foster
David Foster
DIDavid A Ingram
David A Ingram